Interpace Biosciences (IDXG) Stock Price, News & Analysis

Company Overview

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Key Stats

• Today's Range: $2.60 to $2.86
• 50-Day Range: $4.75 to $10.40
• 52-Week Range: $2.57 to $10.42
• Volume: 5,496 shs
• Average Volume: 8,933 shs
• Market Capitalization: $12.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IDXG Stock Analysis - Frequently Asked Questions

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its quarterly earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business services provider earned $8.33 million during the quarter. Interpace Biosciences had a net margin of 10.39% and a negative trailing twelve-month return on equity of 8.09%.

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX).

Company Calendar

• Last Earnings: 3/29/2023
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Services
• Current Symbol: NASDAQ:IDXG
• CUSIP: 69329V10
• CIK: 1054102
• Web: www.interpace.com
• Phone: 855-776-6419
• Fax: 862-207-7820
• Employees: 152
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $800,000.00
• Net Margins: 10.39%
• Pretax Margin: 10.93%
• Return on Equity: -8.09%
• Return on Assets: 37.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $40.21 million
• Price / Sales: 0.31
• Cash Flow: $0.65 per share
• Price / Cash Flow: 4.36
• Book Value: ($14.16) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 4,400,000
• Free Float: 4,155,000
• Market Cap: $12.50 million
• Optionable: Not Optionable
• Beta: 0.74